June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
ARPE-19: the best cell to model retinal diseases in vitro?
Author Affiliations & Notes
  • Audrey Leguen
    Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France
  • Christelle Monville
    I-STEM, EVRY, Ile de France, France
  • Anaïs Balbous-Gautier
    Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France
  • Afsaneh Gaillard
    Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France
  • Nicolas LEVEZIEL
    Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France
    Ophthalmology, CHU Poitiers, Poitiers, Nouvelle Aquitaine, France
  • Footnotes
    Commercial Relationships   Audrey Leguen, None; Christelle Monville, None; Anaïs Balbous-Gautier, None; Afsaneh Gaillard, None; Nicolas LEVEZIEL, None
  • Footnotes
    Support  Région Poitou-Charentes - Novartis
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2285. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Audrey Leguen, Christelle Monville, Anaïs Balbous-Gautier, Afsaneh Gaillard, Nicolas LEVEZIEL; ARPE-19: the best cell to model retinal diseases in vitro?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2285.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : ARPE-19 is currently used as an in vitro model for retinal diseases such as age-related degeneration (AMD). Up to now few studies show morphological and genetic expression differences between ARPE-19 and foetal or adult human retinal pigment epithelial (hRPE) cells. This study aims to compare ARPE-19 to hRPE cells derived from induced pluripotent stem cells (iPS) cells in both normal and oxidative stress condition (Fe-NTA treatment), the study hypothesis being to consider that hRPE-iPS cells are more able than ARPE-19 to model AMD in vitro.

Methods : iPS cell obtained from peripheral venous blood samples of individuals aged more than 60 years were differenciated into hRPE cells (N=4). hRPE-iPS cells were characterized by morphology, immunofluorescence, FACS and RTqPCR. In basal condition, β-galactosidase activity was measured to quantify senescent cells. Cell count was performed manually with ZEN software. Fe-NTA added to the culture media was used to mimic oxidative environment. In vitro concentrations of Fe-NTA was determined to evaluate the toxicity level characterized by cells death by MTT test (n=9). We estimated the oxidative stress produced by detection of DCFH-DA oxidized by ROS (n=9). For phagocytosis activity, cells were fed with fluorescent polyesters beads added into the media during 3 hours. The level of phagocytosis was quantified by FACS during both conditions (100 000 cells count in each experiment). One-way ANOVA was used for statistical analysis.

Results : Only hRPE-iPS cells expressed β-galactosidase activity (64,45±8,31%, cells counts: 12 022), suggesting that these cells have a senescent profile compared to ARPE-19. Under oxidative stress, Fe-NTA levels increase up to 15 mM during 24 hours did not cause a significant decrease in cell viability (while 20 mM, p<0,0001) while inducing oxidative stress (significant from 10 mM, p<0,062). For phagocytosis activity, Fe-NTA concentrations increase induced a significant inhibition of internalization of fluorescent beads in ARPE-19 (from 10 mM, p<0,05) but not significant in hRPE-iPS cells.

Conclusions : Our results are consistent with our hypothesis that ARPE-19 and hRPE-iPS cells differ morphologically and in terms of phagocytosis activity and aging. By consequence, the use of hRPE-iPS cells may be considered as a more reliable model to mimic hRPE cells as an in vitro model of AMD than ARPE-19. Further studies are needed to confirm these results.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×